TTNP

Titan Pharmaceuticals

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 0

Sell signal 1

Revenue Keeps Dropping

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About TTNP

Titan Pharmaceuticals, Inc.

A development stage company that developing therapeutics for central nervous system and other serious medical disorders

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

10/12/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.titanpharm.com

Security Type

Common stock

Office address

10 East 53rd St., Suite 3001, New York, New York 10022

Business

Introduction

Titan Pharmaceuticals, Inc., was incorporated in February 1992 under the laws of the State of Delaware. The company is a pharmaceutical company. The Company is focused on developing therapeutic drugs utilizing ProNeura, a proprietary long-term drug delivery platform, for the treatment of specific chronic diseases where homeostatic delivery has the potential to provide efficacy. ProNeura consists of a small solid implant made of ethylene-vinyl acetate (" EVA ") and a drug mixture. The resulting product is a solid matrix designed for subcutaneous administration in brief outpatient procedures and removed in a similar manner at the end of the treatment period.

Company Financials

EPS

TTNP has released its 2023 Q3 earnings. EPS was reported at -0.40, versus the expected 0.00, missing expectations. The chart below visualizes how TTNP has performed over recent quarters, highlighting trends in earnings surprises.